EcoDrugPlus

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSTNIG00000003705
Gene Symbol: PSMB10
2 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSTNIG00000006995
Gene Symbol: PSMB11B
2 Cross references
159 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSTNIG00000019624
Gene Symbol: PSMB2
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSTNIG00000014144
Gene Symbol: PSMB3
2 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSTNIG00000005387
Gene Symbol: PSMB4
2 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSTNIG00000007949
Gene Symbol: PSMB5
2 Cross references
203 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSTNIG00000001826
Gene Symbol: PSMB6
2 Cross references
230 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSTNIG00000019654
Gene Symbol: PSMB7
2 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSTNIG00000018184
Gene Symbol: PSMB8A
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSTNIG00000018181
Gene Symbol: PSMB9A
2 Cross references
204 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSTNIG00000014301
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSTNIG00000017570
Gene Symbol: PSMD4A
2 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).